Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$4.04 USD
+0.24 (6.32%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $4.05 +0.01 (0.25%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 221 - 240 ( 425 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moving Forward Despite Potential COVID-19 Headwinds
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Pinch of Preclinical Data at AACR and a Punch of Clinical Data in 2H20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
iNK Cell Programs Further De-Risked, Raising PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Increasing PT on More Favorable 2020 Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2019: Hangover: Covered Companies Roundup
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2019: Key Presentations Roundup for Covered Companies Days 1-2
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cell Therapy Programs Begin to Take Shape, SITC and ASH updates Await
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D